Thermo Fisher Scientific has signed a purchase agreement to acquire MTI-GlobalStem, a privately-held company that develops and commercializes leading-edge technology and reagents for cell transfection, neurobiology and stem cell research applications.
Completion of the transaction follows the receipt of all required regulatory approvals. Per the agreement, no further details of the transaction are being provided. Based in Gaithersburg, Md., MTI-GlobalStem will be folded into Thermo Fisher’s life sciences solutions segment.
“The addition of MTI-GlobalStem’s technology further strengthens Thermo Fisher’s leadership in biosciences and provides scientists around the world with access to a wider array of advanced research products designed to help accelerate discovery using cell models,” said Amy Butler, vice president and general manager of Cell Biology for Thermo Fisher Scientific. “Their technology and expertise, combined with Thermo Fisher’s global commercial reach, is a strategic fit that enables us to better serve our transfection and stem cell research customers.”